%0 Journal Article
%T PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab
%A Antonios Papanicolau-Sengos
%A Blake Burgher
%A Carl Morrison
%A Felicia L. Lenzo
%A Jeffrey M. Conroy
%A Jonathan Andreas
%A Lorenzo Galluzzi
%A Mary Nesline
%A Moachun Qin
%A Saby George
%A Sarabjot Pabla
%A Sean T. Glenn
%A Vincent Giamo
%A Yirong Wang
%J Archive of "Oncoimmunology".
%D 2018
%R 10.1080/2162402X.2018.1460298
%X We report the immunological profile of a patient with upper-tract urothelial carcinoma experiencing stable disease on pembrolizumab for 20 months. The tumor exhibited extensive infiltration by CD8+ cytotoxic T lymphocytes, low-to-moderate mutational burden, no PD-L1 staining by commercially available immunohistochemical assays, but amplification of CD274 (coding for PD-L1) and/or PDCD1LG2 (encoding PD-L2) by fluorescence in situ hybridization. RNA-seq revealed multiple biomarkers of an ongoing immune response and compensatory immune evasion, including moderate PD-L1 levels coupled with robust PD-L2 expression. Pending validation in additional patients, these findings suggest that PD-L2 expression levels may constitute a biomarker of response to immune checkpoint blockade in urothelial carcinoma
%K 22C3 assay
%K ADORA2A
%K atezolizumab
%K immunohistochemistry
%K PD-1
%K SP142 assay
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279415/